About Myriad Genetics
Myriad Genetics (NASDAQ:MYGN) is a healthcare company that specializes in genetic testing and precision medicine. The firm focuses on providing tests that assess an individual’s risk of developing disease, guide treatment decisions, and assess risk of disease progression and recurrence. Myriad Genetics operates in several key areas, including hereditary cancer, urology, dermatology, autoimmune diseases, and mental health, striving to deliver actionable insights to both patients and healthcare providers. Their objective is to enhance patient outcomes by integrating genetic insights into healthcare decision-making, promoting a more personalized approach to treatment and preventive care. Through its comprehensive suite of tests, Myriad Genetics aims to empower individuals with valuable health information to make informed decisions about their health and lifestyle, driving forward the evolution of personalized medicine.
Snapshot
Operations
Produtos e/ou serviços de Myriad Genetics
- Genetic Testing: Myriad offers a variety of genetic tests, including carrier screening for hereditary diseases, preimplantation genetic testing (PGT) for embryos, and diagnostic testing for specific conditions like cancer.
- Companion Diagnostics: They develop companion diagnostics, which are tests used alongside specific drugs or therapies to assess a patient's suitability or potential response to treatment.
- Personalized Medicine: Myriad leverages their genetic testing capabilities to support the advancement of personalized medicine initiatives, aiming to tailor healthcare based on individual genetic makeup.
- Lab Services and Clinical Trials: They offer laboratory services and participate in clinical trials to further develop and validate their genetic tests and support ongoing research in the field of molecular diagnostics.
- Partnerships and Collaborations: Myriad collaborates with other companies and institutions to leverage expertise and resources for broader development, commercialization, and adoption of their genetic tests and related services.
- Educational Resources and Advocacy: They may provide educational resources and engage in advocacy efforts to raise awareness about genetic testing, its potential benefits, and ethical considerations.
equipe executiva do Myriad Genetics
- Mr. Samraat S. RahaPresident, CEO & Director
- Mr. Mark S. VerrattiChief Operating Officer
- Dr. Dale Muzzey Ph.D.Chief Scientific Officer
- Mr. Paul J. Diaz J.D.Consultant & Director
- Mr. Benjamin R. WheelerCFO & Principal Accounting Officer
- Dr. Kevin Richard Haas Ph.D.Chief Technology Officer
- Mr. Matthew ScaloSenior Vice President of Investor Relations
- Ms. Jennifer L. Fox J.D.Chief Legal Officer
- Ms. Shereen SolaimanChief People Officer
- Dr. Patrick M. Burke Ph.D.Executive Vice President of Innovation & Strategic Partnerships